Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd, a player in the Commodity Chemicals sector, recorded a new 52-week low of Rs.37.77 today, marking a significant milestone in its ongoing decline. The stock has been under pressure for six consecutive sessions, culminating in a near 10% loss over this period and underperforming its sector by 3.51% on the day.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, witnessed intense selling pressure on 12 Jan 2026, culminating in the stock hitting its lower circuit limit. The share price plunged by 4.35% to close at ₹38.45, marking a new 52-week low of ₹38.19 during intraday trade. This sharp decline reflects mounting investor concerns amid sustained negative momentum and unfilled supply overwhelming demand.

Fischer Medical Ventures Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 5 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, witnessed intense selling pressure on 9 Jan 2026, hitting its lower circuit limit and closing at a new 52-week low of ₹39.15. The stock’s sharp decline reflects mounting investor concerns amid deteriorating technical indicators and a sustained downtrend.

Fischer Medical Ventures Ltd has declined to a fresh 52-week low of Rs.40.5, marking a significant downturn in its stock performance amid broader market resilience. The stock has been on a downward trajectory for five consecutive sessions, reflecting ongoing pressures within the commodity chemicals sector.

Fischer Medical Ventures Ltd has touched a new 52-week low of Rs.40.9 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors. The stock has been on a downward trajectory for four consecutive days, reflecting ongoing challenges within the commodity chemicals sector.

Fischer Medical Ventures Ltd, a key player in the Commodity Chemicals sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite some bullish signals on monthly indicators, the overall technical landscape suggests caution for investors as the stock price hovers near its 52-week low, underperforming the broader market benchmarks.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, surged to hit its upper circuit limit on 1 Jan 2026, propelled by strong buying momentum and heightened investor interest. The stock outperformed its sector and benchmark indices, reflecting renewed optimism despite a recent upgrade to a Hold rating from Sell by MarketsMOJO.

Fischer Medical Ventures Ltd, a key player in the Commodity Chemicals sector, has seen its investment rating upgraded from Sell to Hold as of 29 Dec 2025. This shift reflects a nuanced improvement across technical indicators, financial trends, valuation metrics, and overall quality assessments, signalling cautious optimism amid recent market volatility and company performance.

Fischer Medical Ventures Ltd, a key player in the Commodity Chemicals sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and bullish signals across multiple timeframes. Despite a recent downgrade from a Sell to a Hold rating by MarketsMOJO, the stock’s technical indicators reveal a nuanced picture that investors should carefully analyse amid ongoing market volatility.

Fischer Medical Ventures Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Fischer Medical Ventures Ltd witnessed a robust trading session as it hit the upper circuit price limit, reflecting intense buying interest and a maximum permissible daily gain. The stock outperformed its sector and broader market indices, drawing attention from investors amid a backdrop of falling delivery volumes and regulatory trading restrictions.

Fischer Medical Ventures Ltd witnessed a robust trading session on 18 Dec 2025, hitting its upper circuit price limit as strong buying interest propelled the stock to its maximum daily gain. The surge comes after a brief period of decline, signalling renewed investor enthusiasm in the commodity chemicals sector.

Fischer Medical Ventures, a key player in the Commodity Chemicals sector, has recently undergone a revision in its evaluation metrics reflecting a complex interplay of financial performance, valuation concerns, and technical indicators. Despite notable growth in sales and profits over recent quarters, the stock continues to trail broader market indices, prompting a nuanced reassessment of its investment profile.

Fischer Medical Ventures, a player in the Commodity Chemicals sector, is currently exhibiting a notable shift in its technical momentum, reflecting a complex interplay of bearish and bullish indicators across multiple timeframes. Recent evaluation adjustments highlight a transition towards a more cautious market stance, with key technical parameters signalling a nuanced outlook for investors.

Fischer Medical Ventures Ltd witnessed robust buying interest on 12 Dec 2025, hitting its upper circuit limit and registering a maximum daily gain of 1.34%. The stock’s performance outpaced its sector and benchmark indices, reflecting heightened investor enthusiasm despite a regulatory freeze on further trading.